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Neurofibromatosis type 1 in an adult diagnosed by a pulmonologist
Abstract
Neurofibromatosis type 1 (NF1), referred to as von Recklinghausen’s disease, is a genetic disorder triggered by mutation of
the NF1 gene, resulting in a lack of neurofibromin, which leads to abnormalities found in the peripheral nervous system and
central nervous system, as well as in other organs. The disease is diagnosed early, usually in childhood by pediatricians.
However, in some cases, the disease is clinically silent and remains undiagnosed or is recognized in the late adulthood. We
report a case study of a 32-year-old female, who was referred to the pulmunologist with a suspicion of a lung tumor.  The
patient was admitted to the Pulmonology Department to investigate further the subpleural mass localized in the left lung
found by chance in a chest X-ray. Physical examination revealed café-au-lait spots on her skin, several subcutaneous
nodules which were confirmed by a histopathology to be consistent with neurofibroma. Further diagnostic testing, such as
chest CT, PET and ophthalmological examination, led to diagnosis of neurofibromatosis type 1 with pulmonary involvement.
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Introduction
Neurofibromatosis type 1 (NF1, von Reckling-
hausen’s disease) is a common genetic disorder
that is inherited as an autosomal dominant trait.
The disease is caused by mutation of the NF1 gene,
which leads to lack of protein neurofibromin. As
a consequence, peripheral and central nervous sys-
tem, as well as other organs are involved. The dia-
gnosis of NF1 is usually made in early childhood
by pediatricians. However, in some cases, the di-
sease is clinically silent and remains undiagnosed
or is recognized in the late adulthood.
Case report
A 32-year-old female was admitted to Pulmono-
logy Clinic at the University Hospital in Kraków for
further diagnostic testing of subpleural mass in the
lower lobe of the left lung. The finding was detected
in a chest X-ray  (Figure 1), performed because of pa-
roxysmal dyspnea the patient was complaining of for
about 5–6 years. The dyspnea occurred usually in her
workplace — a tannery.
On admission, the patient was in general good
condition, her hemodynamic and respiratory status
were stable. Physical examination revealed  four cafe-
-au-lait macules  (measuring 45 × 19 mm, 22 × 8 mm,
48 × 19 mm and 30 × 11 mm), three tumors ( 25 × 20 mm
in the left supraclavicular fossa, 25 × 15 mm over
the left breast, and 15 mm in diameter in the right oc-
cipital area), and a nodule 10 mm in diameter on her
back. Patient manifested the above abnormalities se-
veral years prior to the presentation. In 1995 a no-
dule on palmary surface of her left hand was resec-
ted. Histopatological examination was not performed,
however.  She underwent excision of another nodule
from the left suborbital area, which turned out to be
neurofibromatous in skin biopsy in 1997. Since 2001
the patient has been treated by neurologist because of
her epilepsy. Electroencephalogram (EEG) showed
a tendency to paroxysmal discharges. Magnetic reso-
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Figure 1. Patient’s chest radiograph showing two lesions marked
and measured
Figure 2. Patient’s chest CT scanning revealing tumor arising from
the left side of the chest wall
Figure 3. Patient’s chest CT scanning revealing smaller tumor ari-
sing from the right side of the chest wall
nance (MRI) of the brain in 2001 and computed to-
mography (CT) with contrast in 2008 did not reveal
any focal changes. Family history was insignificant.
On subsequent chest X-ray performed in the
Pulmonology Departament  another, smaller no-
dule in the upper lobe of the right lung was fo-
und (Figure 1). CT with contrast demonstrated
a 38 × 33 × 24 mm mass localized on the left side
of the thorax in the midaxillary line, in the inter-
costal space over the costophrenic angle, tightly
adjacent to the thoracic wall, accompanied by sli-
ght compressive osteolysis of the adherent ribs
(Figure 2). Another finding was a  mass on the ri-
ght side of the chest at the level of bifurcation of
the trachea, measuring  19 × 8 mm, also directly
connected with the thoracic wall (Figure 3).  In
summary a radiologist stated “diagnostic image of
tumorous changes of the chest, which may origi-
nate from intercostal nerves”. Taking moderate
enlargement of the anterior aortal lymph nodes
(16 × 12 mm) into consideration, positron emis-
sion tomography (PET) was recommended. Howe-
ver, it did not reveal pathological acquisition of
marker in thoracic tumours.  The patient was re-
ferred to surgery and subsequently underwent re-
moval of the largest skin lesion — an oval, mova-
ble nodule in the left supraclavicular fossa. Skin
biopsy confirmed neurofibroma. Ophthalmologi-
cal examination revealed Lisch nodules in both
irises. Suspicion of von Recklinghausen’s disease
was made. The patient was referred to genetic
outpatient’s clinic at Children’s University Hospi-
tal in Kraków. Based on patient’s history, physi-
cal examination (morphology of tumors and cu-
taneous nodules specific for neurofibromatosis) it
was established the patient meets the criteria for
NF1. Given the negative family history in respect
to neurofibromatosis, it was also determined that
disorder was a result of de novo mutation. Further
observation of the subject was recommended due
to variability of the symptoms in NF1.
After 3 months CT of the chest was repeated.
No differences in  pulmonary findings was noted.
Patient complained of dyspnea, nevertheless spi-
rometry was normal.  We did not ordered a hy-
persensitivity test, due to coexisting epilepsy,
which is a contraindication to consecutive spiro-
metry tests. The patient’s history revealed that
dyspnea occurred only in her workplace (tanne-
ry), particularly in rooms with high chemical con-
centration in air. The patient was referred for an
occupational diseases’ specialist evaluation with
a suspicion of an occupational asthma. She rema-
ined under continuous neurologic control. MRI of
the brain and medulla was performed periodically.
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Discussion
Epidemiology and pathogenesis
Neurofibromatosis type 1 is a relatively com-
mon (birth incidence 1:2500–1:3000) genetic dise-
ase that is inherited as an autosomal dominant trait.
It is one of the phakomatoses (Greek phakoma
meaning naevus). The disease often remains un-
diagnosed, due to its discrete clinical manifesta-
tion, different clinical expression even in members
of the same family. Phenotypic expression may also
be age-dependent.
Molecular background NF1
NF 1 is a genetically inherited autosomal domi-
nant disease associated with a single NF1 gene mu-
tation. It has been proven to have penetration (pro-
bability of disease occurrence in a mutation’s carrier)
approaching 100% and highly variable expression
(that is different clinical manifestation in an affec-
ted family as well as between families). NF1 has its
own catalogue number (+162200) in a directory of
genetic diseases in man (MIM — Mendelian Inheri-
tance in Man, also referred to as  McKusick catalo-
gue). NF1 gene is localized in 17q1.2  region [1], and
encodes protein neurofibromin. A half of new cases
is a result of de novo mutations and has no heredita-
ry background. Offspring inherits the disease with
a typical risk of 50% [2]. Product of NF1 gene, neuro-
fibromin, belongs to the family of proteins that are
responsible for GTP-ase activation. It is also an inhi-
bitor of protooncogene p21ras. Thus, NF1 gene is
a suppressor gene for carcinogenesis [3, 4]. Lack of neu-
rofibromin leads to the development of both benign
and malignant tumors, such as: rhabdomyosarcomas,
malignant peripheral nerve sheath tumors (MPNST),
also known as neurosarcomas (originating from ple-
xiform fibromas) and leukemias.
Symptoms and diagnosis
The diagnosis of NF 1 is made usually based
on physical examination, which includes presen-
ce of so-called large (main) and small (additional)
symptoms. Large symptoms comprise (in brackets
— incidence):
— café-au-lait spots (>99%),
— freckling and hyperpigmentation (70%),
— peripheral fibromas (>99%),
— iris hamartomas (Lisch nodules) with no vi-
sion disturbances (>90%).
Small symptoms consist of: macrocephaly
(45%) and short stature (30%). In afflicted sub-
jects secondary symptoms and complications
may appear, such as: mental retardation (30%),
epilepsy (30%), plexiform fibromas that may
undergo malignant transformation (35%). Ortho-
pedic complications (25%) are due to  bone dys-
plasia and deformations, which most commonly
cause thoracic scoliosis. Renal artery stenosis is
relatively rare (1,5%), may however lead to secon-
dary nephrogenic hypertension. Central nervous
system tumors, most often optic nerve gliomas,
affect small percentage of patients and typically
present early in life. There is 2,5–4 fold higher risk
of the above-mentioned malignancy in NF1 pa-
tients when compared to general population [5, 6].
Molecular diagnostic testing is not necessary to
establish a diagnosis of NF1. In Poland it is  routi-
nely inaccessible. Both large and small symptoms
tend to vary in a lifetime; therefore prognosis on
disease course is impossible.
Obligatory diagnostic criteria of NF1 (NF1 NIH
Consensus Conference Criteria [7]) were stated in
1997 and sustained in 2007 [8].  Neurofibromato-
sis type 1 is diagnosed when 2 or more of the fol-
lowing criteria are met:
— six or more café-au-lait spots > 5 mm in diame-
ter prior to puberty or > 15mm post puberty,
— two or more typical neurofibromas of any type
or one plexiform neurofibroma,
— freckles/hyperpigmentation spots in areas in-
accessible to light (axillary, groin),
— two or more iris hamartomas (Lisch nodules),
— typical bone abnormalities,
— first-degree relative meeting the above criteria.
Management
Causal treatment is not possible, therefore
symptomatic therapy is recommended. Patients
require continuous care due to variability of clini-
cal features in life. Patient should also be monito-
red due to the possibility of malignant transforma-
tion of tumours.
Conclusions
The presented case study is an example of late
and accidental diagnosis of NF 1 due to paucity of
its symptoms. Developmental disturbances in in-
fancy or signs of the disease that could make the
suspicion of NF1 possible were not observed. In
adulthood, symptoms most probably unrelated to
NF1 (bronchial asthma) contributed to chest X-ray,
which subsequently revealed pulmonary masses
and led to further diagnostic testing.
Manifestations of NF 1 in chest comprise:
— in lungs:
• interstitial lung disease (however, it rema-
ins controversial whether it truly is asso-
ciated with NF1) [9, 10],
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• metastases of neurosarcomas (generally of
a very bad prognosis, despite reports on 5-
-years’ survival after metastasis resection) [11];
— in mediastinum:
• meningocele,
• neurofibromas of vagal nerve;
— in thorax wall:
• subcutaneous neurofibromas,
• costal dural ectasias due to intercostal neu-
rofibromas compression,
• kyphoscoliosis,
• pulmonary apex neurofibromas (Pancoast’s
syndrome) [12].
In presented case one of the masses, adjacent to
the thorax wall, manifested as pulmonary tumor on
chest X-ray. Finally, CT visualized precise localiza-
tion of the change and its relation to neighbouring
structures in the chest. It also revealed other findings
in the chest wall. Additionally, osteolysis of the ribs
due to compression by the largest lesion was noted,
which corresponded with dural ectasias described in
literature [12]. Taking typical picture of the findings
in CT and clinical manifestation as a whole into con-
sideration, we restrained from invasive diagnostic
testing. Due to risk of potential neoplastic transfor-
mation of the existing neurofibromas, careful obser-
vation and regular chest CT were recommended.
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